{"id":"demexiptiline","rwe":[{"pmid":"34389045","year":"2021","title":"Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","finding":"","journal":"Systematic reviews","studyType":"Clinical Study"},{"pmid":"34034811","year":"2021","title":"Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.","finding":"","journal":"Systematic reviews","studyType":"Clinical Study"},{"pmid":"8370568","year":"1993","title":"Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice.","finding":"","journal":"Fundamental & clinical pharmacology","studyType":"Clinical Study"},{"pmid":"7337336","year":"1981","title":"[Demexiptiline in the treatment of melancholic states (reflections after 3 years of use)].","finding":"","journal":"Annales medico-psychologiques","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Depressive disorder","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"deparon","offLabel":[],"synonyms":["demexiptiline","deparon"],"timeline":[],"approvals":[],"brandName":"Deparon","ecosystem":[{"indication":"Depressive disorder","otherDrugs":[{"name":"amitriptyline","slug":"amitriptyline","company":"Astrazeneca"},{"name":"amoxapine","slug":"amoxapine","company":"Lederle"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"citalopram","slug":"citalopram","company":"Forest Labs"}],"globalPrevalence":280000000}],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your brain is a complex communication network. Neurotransmitters are like messengers that help different parts of the brain talk to each other. Deparon may help regulate the levels of these messengers to improve mood and reduce symptoms of depression.","oneSentence":"Deparon is thought to work by influencing neurotransmitter levels in the brain.","technicalDetail":"Deparon's exact mechanism of action is unclear, but it is likely to interact with serotonin and/or other neurotransmitter systems to produce its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/804","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEMEXIPTILINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:27:38.407998","biosimilars":[],"competitors":[],"genericName":"demexiptiline","indications":{"approved":[{"name":"Depressive disorder","source":"DrugCentral","snomedId":35489007,"regulator":"FDA","usPrevalence":21000000,"globalPrevalence":280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"EYX738UZ5P","CHEBI":"CHEBI:135152","INN_ID":"4834","UMLSCUI":"C0615823","ChEMBL_ID":"CHEMBL2107576","DRUGBANK_ID":"DB08998","PUBCHEM_CID":"28876","MESH_SUPPLEMENTAL_RECORD_UI":"C033781"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2021 Aug 13","pmid":"34389045","title":"Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","journal":"Systematic reviews"},{"date":"2021 May 25","pmid":"34034811","title":"Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.","journal":"Systematic reviews"},{"date":"1993","pmid":"8370568","title":"Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice.","journal":"Fundamental & clinical pharmacology"},{"date":"1981 Nov","pmid":"7337336","title":"[Demexiptiline in the treatment of melancholic states (reflections after 3 years of use)].","journal":"Annales medico-psychologiques"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deparon (DEMEXIPTILINE) is a small molecule drug with unknown drug class and target. It is used to treat depressive disorder, but its commercial status and key safety considerations are currently unknown. Further research is needed to determine its pharmacokinetic properties and potential side effects. Deparon's exact mechanism of action is also unclear, but it is likely to modulate neurotransmitter activity in the brain. As a result, its development and approval status are uncertain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}